Amedisys (NASDAQ: AMED) was upgraded by Robert W. Baird from a “neutral” rating to an “outperform” rating in a research note issued on Tuesday. The firm currently has a $10.00 price target on the stock, up from their previous price target of $9.00.
A number of other analysts have also recently weighed in on AMED. Analysts at Jefferies Group (NYSE: JEF) cut their price target on shares of Amedisys from $16.50 to $15.00 in a research note to investors on Wednesday, May 9th. They now have a “hold” rating on the stock. Separately, analysts at CRT Capital upgraded shares of Amedisys to a “sell” rating in a research note to investors on Monday, April 23rd.
Amedisys traded down 0.29% on Tuesday, hitting $10.28. Amedisys has a 52-week low of $9.12 and a 52-week high of $34.42. The company’s market cap is $309.7 million.
Amedisys last announced its earnings results on Tuesday, May 8th. The company reported $0.22 earnings per share for the quarter, meeting the analysts’ consensus estimate of $0.22. Amedisys’s revenue was up 3.2% compared to the same quarter last year. On average, analysts predict that Amedisys will post $0.26 earnings per share next quarter.
Amedisys, Inc. (Amedisys) is a provider of home health services to the chronic, co-morbid, aging American population.